Chiropractors in Norway, ME Accepting Medicare

4 Chiropractors found. Showing 1 - 4

Paul Conrad Brooks, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2 Grove St., Norway, ME 04268 Phone: 207-743-8471    Fax: 207-743-3979

Grant Lemire, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 39 Paris St, Norway, ME 04268 Phone: 207-743-2866    Fax: 207-743-5942

Knopp Chiropractic, Inc. Chiropractor Medicare: Medicare Enrolled Practice Location: 39 Paris St, Norway, ME 04268 Phone: 207-743-2866    Fax: 207-743-5942

Dr. Barry E Knopp, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 39 Paris St, Norway, ME 04268 Phone: 207-743-2866    Fax: 207-743-5942

News Archive

Scientists create simple chemical system that mimics DNA

A team of Scripps Research scientists has created a new analog to DNA that assembles and disassembles itself without the need for enzymes. Because the new system comprises components that might reasonably be expected in a primordial world, the new chemical system could answer questions about how life could emerge.

MU researchers successfully treat dogs with DMD, plan for human clinical trials

Muscular dystrophy, which affects approximately 250,000 people in the U.S., occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function. For years, scientists have searched for a way to successfully treat the most common form of the disease, Duchenne Muscular Dystrophy (DMD), which primarily affects boys. Now, a team of University of Missouri researchers have successfully treated dogs with DMD and say that human clinical trials are being planned in the next few years.

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.

USPTO issues Notice of Allowances to Lakewood's three patent applications for treatment of HUS

Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued Notice of Allowances on three patent applications relating to the use of novel monoclonal antibodies for the treatment of hemolytic uremic syndrome caused by shiga toxin II secreting E.coli O157: H7 strain.

Physical symptoms such as nausea and shortness of breath, may predict shorter survival for patients with terminal cancer

A new study published July 26, 2004 in the online edition of CANCER, a peer-reviewed journal of the American Cancer Society, finds a patient's symptoms and results of quality of life assessments may provide important clues to an individual patient's prognosis. Psychosocial factors, such as anxiety or spiritual distress, did not predict shorter survival.

Read more Medical News

› Verified 1 days ago